Tuesday

6th Dec 2016

EU fines pharma-giants €427mn in ‘pay for delay’ case

  • French pharma-giant Servier was among a string of firms fined over €400 million in the EU's largest 'pay for delay' case. (Photo: Grumpy-Puddin)

French pharmaceutical firm Servier will bear the brunt of a €427 million anti-trust fine in the largest ‘pay for delay’ case brought by the European Commission.

Speaking at a news conference on Wednesday (9 July), EU competition commissioner Joaquin Almunia said Servier was guilty of protecting its bestselling blood pressure drug, perindopril, from price competition by generics in the EU between 2005 and 2007.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

Perindopril generated more than $1 billion per year in sales for Servier, revenues which the company feared it would lose when its patent control over the drug’s molecule expired. Servier then bought the technology needed to develop an alternative version and made a series of patent settlements with companies trying to produce generic forms of the drug.

Servier now faces a €330 million fine, while Niche/Unichem, Matrix Teva, Krka and Lupin - all producers of generic medicines - face fines totalling €97 million.

Internal documents of one generic company acknowledged that it was being "bought out of perindopril," while another insisted that any settlement with Servier would have to be for a "pile of cash".

Describing the behaviour as a “serious breach” of the bloc’s competition rules, Almunia added that “’pay for delay’ is clearly not acceptable”.

For its part, Servier’s spokesperson Lucy Vincent described the ruling as “a bad sign” and indicated that the company plans to appeal. Servier had “acted in a transparent and legitimate way to defend its patents,” she said.

The case is the largest "pay for delay" case brought by the EU executive, where a company has paid off rival firms to prevent them producing cheaper generic versions of a drug.

Pharmaceutical firms use a variety of means including secondary patents and ‘pay for delay’ settlements to prevent rivals from producing generic version of their drugs at a fraction of the price.

But anti-trust regulators in the US and the EU are now investigating a series of similar cases.

Last November, the Commission fined Johnson & Johnson, Novartis, and Lundbeck for paying off their rivals in the EU’s first ‘pay for delay’ cases.

“A company tried hard to unduly prolong its exclusively … not thanks to its innovation and the strength of its patents but thanks to its deep pockets and the complicity of its rivals,” commented Almunia.

“Pharmaceuticals companies should focus their efforts on innovating rather than trying to extract extra rents for patients and taxpayers,” he added.

Merkel calls for Muslim veil ban

German chancellor endorses partial ban on the full-face Muslim veil amid tougher talk on migrants to rally the support of Christian Democrats ahead of a tough election next year.

EU ministers approve 'Juncker plan' extension

The agreement to prolong the EU investment plan until 2020 to raise up to €500 billion will have to be confirmed by the parliament amid questions about its impact and functionning.

Stakeholders' Highlights

  1. European Jewish CongressEJC President Breathes Sigh of Relief Over Result of Austrian Presidential Election
  2. CESICongress Re-elects Klaus Heeger & Romain Wolff as Secretary General & President
  3. European Gaming & Betting AssociationAustrian Association for Betting and Gambling Joins EGBA
  4. ACCAWomen of Europe Awards: Celebrating the Women who are Building Europe
  5. European Heart NetworkWhat About our Kids? Protect Children From Unhealthy Food and Drink Marketing
  6. ECR GroupRestoring Trust and Confidence in the European Parliament
  7. UNICEFChild Rights Agencies Call on EU to put Refugee and Migrant Children First
  8. MIRAIA New Vision on Clean Tech: Balancing Energy Efficiency, Climate Change and Costs
  9. World VisionChildren Cannot Wait! 7 Priority Actions to Protect all Refugee and Migrant Children
  10. ANCI LazioRegio-Mob Project Delivers Analysis of Transport and Mobility in Rome
  11. SDG Watch EuropeCivil Society Disappointed by the Commission's Plans for Sustainable Development Goals
  12. PLATO15 Fully-Funded PhD Positions Open – The Post-Crisis Legitimacy of the EU (PLATO)

Latest News

  1. EU ministers approve 'Juncker plan' extension
  2. Commission tries to revive GMO opt-out proposal
  3. Merkel calls for Muslim veil ban
  4. Russia pipeline is security 'threat', US diplomat says
  5. Brexit deal must be done by October 2018, says EU negotiator
  6. Rising to the challenge of 'European Angst'
  7. Polish firm sues EU Commission over Gazprom privileges
  8. ID and police checks await all who enter and leave the EU